Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Axsome Thera (NQ: AXSM )

71.98 USD UNCHANGED
Streaming Delayed Price Updated: 7:55 AM EST, Feb 25, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Axsome Thera

< Previous 1 2 3 4 5 6 7 Next >
Axsome Therapeutics Initiates GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, enrolled the first patient... 
From GlobeNewswire News Releases
Axsome Therapeutics Provides Update on Continued Progress at Annual Stockholders’ Meeting
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, is providing the following... 
From GlobeNewswire News Releases
Axsome Therapeutics To Present Data From ASCEND Phase 2 Trial Of AXS-05 In Major Depressive Disorder At The 2019 American Society For Clinical Psychopharmacology Annual Meeting
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that data... 
From GlobeNewswire News Releases
Biotech Stocks: Latest Technological Developments Pushing U.S. Medical Device Market to New Levels
Financialnewsmedia.com News Commentary 
From PR Newswire
Biotech Stocks: Latest Technological Developments Pushing U.S. Medical Device Market to New Levels
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Axsome Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial... 
From GlobeNewswire News Releases
Axsome Therapeutics Announces Acceleration of MOMENTUM Phase 3 Trial of AXS-07 in Migraine
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the... 
From GlobeNewswire News Releases
Axsome Therapeutics Announces Expedited Development and Pivotal Status for AXS-05 in the Treatment of Major Depressive Disorder based on FDA Breakthrough Therapy Meeting
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that the... 
From GlobeNewswire News Releases
Axsome Therapeutics To Report First Quarter 2019 Financial Results On May 9, 2019
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it... 
From GlobeNewswire News Releases
Biotech Brief: Optimism Rising for Cancer Treatment Advancements in 2019
Financialnewsmedia.com News Commentary 
From PR Newswire
Biotech Brief: Optimism Rising For Cancer Treatment Advancements In 2019
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Smoking Cessation
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Duke... 
From GlobeNewswire News Releases
Market Trends Toward New Normal in BlackBerry, Axsome Therapeutics, Pulse Biosciences, Whitestone REIT, Anworth Mortgage Asset, and Synchronoss Technologies — Emerging Consolidated Expectations, Analy
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of BlackBerry Limited (NYSE:BB),... 
From GlobeNewswire News Releases
Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Major Depressive Disorder
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that the... 
From GlobeNewswire News Releases
Axsome Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial... 
From GlobeNewswire News Releases
Axsome Therapeutics Secures $24 Million Growth Capital Loan Facility Led by Silicon Valley Bank
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, has entered into a $24... 
From GlobeNewswire News Releases
Axsome Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results on March 14, 2019
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it... 
From GlobeNewswire News Releases
Axsome Therapeutics Initiates MOMENTUM Phase 3 Trial of AXS-07 in Migraine
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, enrolled the first patient... 
From GlobeNewswire News Releases
Biotechnology Companies See Growth in Optic Treatment Sectors
FinancialBuzz.com News Commentary 
From PR Newswire
Axsome Therapeutics Receives FDA Agreement under Special Protocol Assessment (SPA) for the MOMENTUM Phase 3 Trial of AXS-07 in Migraine
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, has reached agreement with... 
From GlobeNewswire News Releases
Axsome Therapeutics Initiates Phase 2 Trial of AXS-12 in Narcolepsy
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, has initiated the CONCERT... 
From GlobeNewswire News Releases
Why Clinical Trial Advantages and Regulatory Process in EU may Hold Advantages Over the U.S.
From PR Newswire
Why Clinical Trial Advantages And Regulatory Process In EU May Hold Advantages Over The U.S.
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Thinking about buying stock in Apple, Axsome Therapeutics, Luxoft, Netflix or QEP Resources?
InvestorsObserver issues critical PriceWatch Alerts for AAPL, AXSM, LXFT, NFLX, and QEP. 
From PR Newswire
Axsome Therapeutics Raises $23.3 Million Under Existing ATM Facility
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announced that today it... 
From GlobeNewswire News Releases
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Major Depressive Disorder
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that... 
From GlobeNewswire News Releases
New Research: Key Drivers of Growth for Trimble, Maxar Technologies, MagnaChip Semiconductor, Palo Alto Networks, AAR, and Axsome Therapeutics — Factors of Influence, Major Initiatives and Sustained P
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Trimble Inc. (NASDAQ:TRMB),... 
From GlobeNewswire News Releases
Axsome Therapeutics Provides Year End 2018 Clinical Update
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today provided the... 
From GlobeNewswire News Releases
Axsome Therapeutics to Present at Biotech Showcase 2019
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that... 
From GlobeNewswire News Releases
Axsome Therapeutics Announces Positive Outcome of Interim Analysis of ADVANCE-1 Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease Agitation
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced a positive... 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.